Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.55 |
| ▸ | HBB | P68871 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | OXTR | P30559 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | SCN4A | P35499 | 7/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SCN1A | P35498 | 2/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4064001 | 0.81 | KDM4E (0.63) | KEAP1KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL1014038 | 0.81 | KEAP1 (1.00) | KEAP1KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL4064464 | 0.81 | KEAP1 (0.77) | KEAP1KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL10271917 | 0.78 | KEAP1 (0.59) | KEAP1KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL23926974 | 0.78 | KDM4E (0.51) | KEAP1KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL30079731 | 0.78 | KDM4E (0.51) | KEAP1KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL11216946 | 0.74 | KDM4E (0.61) | KEAP1KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL12593846 | 0.74 | KEAP1 (0.62) | KEAP1KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL1980444 | 0.73 | KEAP1 (0.75) | KEAP1KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL8736385 | 0.73 | KDM4E (0.69) | KEAP1KDM4EMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200163964-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-20200163964-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-10632118-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-04-28 | — | — | US | disclosed |
| US-10632118-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-04-28 | — | — | US | disclosed |
| US-20180338974-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-11-29 | — | — | US | disclosed |
| US-10058551-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-08-28 | — | — | US | disclosed |
| US-20180021336-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-20180021336-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-20180021336-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-9849131-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2017-12-26 | — | — | US | disclosed |
| US-9216967-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-12-22 | — | — | US | disclosed |
| US-8722695-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2014-05-13 | — | — | US | disclosed |
| US-8722695-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2014-05-13 | — | — | US | disclosed |
| US-8722695-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2014-05-13 | — | — | US | disclosed |
| US-20120289526-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-11-15 | — | — | US | disclosed |
| US-20120289526-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-11-15 | — | — | US | disclosed |
| US-20120289526-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-11-15 | — | — | US | disclosed |
| EP-2509961-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | Autifony Therapeutics Limited (GB) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011069951-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011069951-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180338974-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | KEAP1 3193/4885KDM4E 268/4885MEN1 1190/4885 |
| US-20180021336-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | KEAP1 3193/4885KDM4E 268/4885MEN1 1190/4885 |
| US-10632118-B2 | Imidazolidinedione derivatives | KCND3, KCNK3, KCNA3 | KEAP1 3193/4885KDM4E 268/4885MEN1 1190/4885 |
| US-10058551-B2 | Imidazolidinedione derivatives | KCND3, KCNK3, KCNA3 | KEAP1 3193/4885KDM4E 268/4885MEN1 1190/4885 |
| US-20200163964-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | KEAP1 3193/4885KDM4E 268/4885MEN1 1190/4885 |
| US-20120289526-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | KEAP1 2956/4885KDM4E 280/4885MEN1 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.